AZN : Imfinzi Combination Reduces Risk Of Disease Progression Or Death By 45% In Endometrial Cancer

(RTTNews) - AstraZeneca (AZN.L, AZN) said that results from the primary analysis of the DUO-E Phase III trial showed that Imfinzi (durvalumab) plus platinum-based chemotherapy, followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib), both demonstrated a statist https://www.nasdaq.com/articles/azn-:-imfinzi-combination-reduces-risk-of-disease-progression-or-death-by-45-in